Belgium· BE-AMP-SAM472231-00
Vantobra 170 mg
A tobramycin product containing tobramycin, registered in Belgium by PARI Pharma. The same ATC class is registered in 15 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Tobramycin is registered in 15 of 19 countries.
Countries holding a registration under ATC J01GB01 (tobramycin), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Tobramycin · ATC J01GB01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tobramycin costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tobramycin · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$98.67
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Tobramycin
- Manufacturer
- PARI Pharma
- Country
- Belgium (BE)
- ATC code
- J01GB01
- ATC class
- Tobramycin
- Defined daily dose
- 0.3 g, Inhal
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
191 interactions on record for tobramycin.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tobramycin · interactions on record
191 records
- 29 severe
- 62 moderate
- 2 minor
- 98 info
Most severe, free to view
- Magnesium sulfateA06AD04severe
- MannitolA06AD16severe
- Polymyxin BA07AA05severe
- Magnesium sulfateA12CC02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tobramycin in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenVantobra 170 mg Lösning för nebulisatorPARI Pharma GmbH
- SpainVANTOBRA 170 MG SOLUCION PARA INHALACION POR NEBULIZADORPari Pharma Gmbh
- FinlandVantobraPARI Pharma GmbH
- IrelandVantobra 170 mg nebuliser solutionPARI Pharma GmbH
- NetherlandsVantobra 170 mg, verneveloplossingPARI PHARMA GmbH
- PolandVantobraPARI Pharma GmbH
- IcelandVantobraPARI Pharma GmbH
- United StatesBETHKISChiesi USA, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Bramitob, Tobi
- Bulgaria · Tобрекс, Тобрамизил
- Cyprus · Bramitob, Ikobel
- Czechia · Bramitob, Tobramycin Vioser
- Germany · Bramitob, Gernebcin
- Denmark · Nebcina, Tobi
- Estonia · Tobramycin Via Pharma, Tobrex
- Spain · Bramitob, Tobrabact
- Finland · Tobi
- France · Nebcine, Tobi
- United Kingdom (Northern Ireland) · Bramitob, Munuza
- Greece · Bramitob, Eyetobrin
- Croatia · Bramitob, Tobrex
- Hungary · Bramitob, Brulamycin
- Ireland · Bramitob, Tobi
- Iceland · Tobi Podhaler, Vantobra
- Italy · Bramicil, Bramitob
- Liechtenstein · Tobi Podhaler, Vantobra
- Lithuania · Bramitob, Tobramycin Via Pharma
- Luxembourg · Obracin, Tobi
- Latvia · Bramitob, Tobramycin Via Pharma
- Malta · Tobi, Tobrex
- Netherlands · Bramitob, Obracin
- Norway · Bramitob, Nebcina
- Poland · Bramitob, Tobramycin Via Pharma
- Portugal · Bramitob, Tobi
- Romania · Tobi, Tobramicină Sun
- Sweden · Bramitob, Nebcina
- Slovenia · Tobrex
- Slovakia · Bramitob, Tobrex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cccfffc3-5d5f-4baa-b7ca-5020ed5f2e89 GET /v1/drugs/cccfffc3-5d5f-4baa-b7ca-5020ed5f2e89?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Nebuliser solution",
"source": "afmps",
"status": "REVOKED",
"name_en": "Vantobra 170 mg",
"name_fr": "Vantobra 170 mg",
"name_nl": "Vantobra 170 mg",
"amp_code": "SAM472231-00",
"strengths": [
"170.0000",
"170.0000"
],
"pack_count": 1,
"substances": [
"Tobramycin"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Tobramycin",
"authorisation_numbers": [
"EU/1/14/932/001"
]
}See everything about tobramycin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.